CHMP recommends Xadago (safinamide) for Parkinsons Disease.-Zambon
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xadago (safinamide) from Zambon, 50 mg and 100 mg, film-coated tablet intended for the treatment of Parkinson’s disease. The active substance of Xadago is safinamide, a highly selective and reversible MAO-B inhibitor causing an increase in extracellular levels of dopamine in the striatum. Xadago is also associated with state dependent inhibition of voltage-gated sodium (Na+) channels, and modulation of stimulated release of glutamate.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.